Table 1 |
||||||
|
Baseline sociodemographic, clinical, and laboratory characteristics of RA patients in the CLEAR registries as a function of the presence of erosions or rheumatoid nodules |
||||||
|
Radiographic erosions |
Rheumatoid nodules |
|||||
|
|
|
|||||
|
Variable |
Present n = 185 |
Absent n = 276 |
Pf |
Present n = 156 |
Absent n = 593 |
Pf |
|
|
||||||
|
Age at RA onset, years, mean (SD) |
45.3 (14.5) |
48.3 (12.6) |
0.02 |
45.6 (12.6) |
47.8 (13.6) |
0.06 |
|
Disease duration,a years, median (IQRb) |
3.8 (1.2-15.5) |
1.2 (6.0-2.0) |
<0.0001 |
7.5 (1.3-15.6) |
1.8 (0.8-8.0) |
<0.001 |
|
Smoking, ever,c n (%) |
98 (54.4) |
139 (51.9) |
0.59 |
95 (61.7) |
295 (50.3) |
0.01 |
|
HAQd score, median (IQR) |
2.0 (1.3-2.4) |
1.8 (0.9-2.4) |
0.27 |
2.1 (1.3-2.6) |
1.8 (1.0-2.4) |
0.01 |
|
Joint-space narrowing at baseline, present (score >0), n (%) |
132 (71.4) |
34 (12.3) |
<0.001 |
48 (53.3) |
116 (31.9) |
<0.001 |
|
Rheumatoid factor positive, n (%) |
145 (87.3) |
182 (74.3) |
0.001 |
127 (90.7) |
418 (77.1) |
<0.001 |
|
Anti-CCP antibody positive, n (%) |
148 (81.3) |
159 (59.3) |
<0.001 |
127 (84.1) |
375 (65.2) |
<0.001 |
|
Abnormal C-reactive protein (>5 mg/L), n (%) |
94 (51.9) |
126 (46.5) |
0.26 |
77 (58.8) |
238 (44.7) |
<0.004 |
|
HLA-DRB1 present,e n (%) |
78 (42.9) |
113 (41.1) |
0.71 |
64 (43.2) |
234 (39.9) |
0.45 |
|
Methotrexate use, ever,c n (%) |
149 (82.3) |
175 (64.6) |
<0.001 |
127 (81.9) |
423 (72.2) |
0.01 |
|
|
||||||
|
aDisease duration at enrollment: duration between self-reported onset of symptoms and date of enrollment; bIQR interquartile range (25th and 75th); ccurrent or past; dHeath Assessment Questionnaire; eHLADRB1 was made to determine SE positive; fTwo-tailed P value by independent-sample t test, Wilcoxon rank-sum test, or χ2 test for proportions, as appropriate and wherever applicable, missing data were excluded from the denominator for calculating percentage and P value. |
||||||
|
Burgos et al. Arthritis Research & Therapy 2010 12:R75 doi:10.1186/ar2994 |
||||||
